Jeff Yass’s Abeona Therapeutics ABEO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $805K | Sell |
130,300
-253,600
| -66% | -$1.39M | ﹤0.01% | 8766 |
|
|
2026
Q1 | $1.72M | Buy |
383,900
+174,000
| +83% | +$870K | ﹤0.01% | 6530 |
|
|
2025
Q4 | $1.11M | Buy |
209,900
+16,200
| +8% | +$81.5K | ﹤0.01% | 6947 |
|
|
2025
Q3 | $1.02M | Buy |
193,700
+73,700
| +61% | +$467K | ﹤0.01% | 7306 |
|
|
2025
Q2 | $682K | Buy |
120,000
+97,300
| +429% | +$554K | ﹤0.01% | 8432 |
|
|
2025
Q1 | $108K | Buy |
+22,700
| New | +$123K | ﹤0.01% | 11491 |
|
|
2024
Q4 | – | Sell |
-27,000
| Closed | -$171K | – | 12072 |
|
|
2024
Q3 | $171K | Buy |
27,000
+9,400
| +53% | +$49.1K | ﹤0.01% | 10617 |
|
|
2024
Q2 | $74.6K | Buy |
17,600
+4,100
| +30% | +$20.9K | ﹤0.01% | 11210 |
|
|
2024
Q1 | $97.9K | Sell |
13,500
-22,100
| -62% | -$140K | ﹤0.01% | 11231 |
|
|
2023
Q4 | $178K | Buy |
+35,600
| New | +$157K | ﹤0.01% | 10798 |
|
|
2021
Q3 | – | Sell |
-736
| Closed | -$29K | – | 12640 |
|
|
2021
Q2 | $29K | Sell |
736
-1,380
| -65% | -$56.3K | ﹤0.01% | 12389 |
|
|
2021
Q1 | $99K | Buy |
2,116
+1,648
| +352% | +$90.8K | ﹤0.01% | 11865 |
|
|
2020
Q4 | $18K | Buy |
+468
| New | +$15.9K | ﹤0.01% | 10890 |
|
|
2020
Q3 | – | Sell |
-1,056
| Closed | -$77K | – | 10466 |
|
|
2020
Q2 | $77K | Sell |
1,056
-752
| -42% | -$52K | ﹤0.01% | 9609 |
|
|
2020
Q1 | $95K | Buy |
1,808
+576
| +47% | +$38.5K | ﹤0.01% | 9355 |
|
|
2019
Q4 | $101K | Buy |
1,232
+636
| +107% | +$44.9K | ﹤0.01% | 9134 |
|
|
2019
Q3 | $34K | Buy |
596
+156
| +35% | +$11.7K | ﹤0.01% | 9868 |
|
|
2019
Q2 | $53K | Sell |
440
-452
| -51% | -$75.8K | ﹤0.01% | 9827 |
|
|
2019
Q1 | $164K | Sell |
892
-1,484
| -62% | -$265K | ﹤0.01% | 7982 |
|
|
2018
Q4 | $424K | Sell |
2,376
-680
| -22% | -$148K | ﹤0.01% | 6345 |
|
|
2018
Q3 | $978K | Sell |
3,056
-4,020
| -57% | -$1.43M | ﹤0.01% | 5252 |
|
|
2018
Q2 | $2.83M | Buy |
7,076
+1,304
| +23% | +$570K | ﹤0.01% | 3467 |
|
|
2018
Q1 | $2.07M | Sell |
5,772
-2,652
| -31% | -$985K | ﹤0.01% | 3848 |
|
|
2017
Q4 | $3.34M | Buy |
8,424
+480
| +6% | +$199K | ﹤0.01% | 3070 |
|
|
2017
Q3 | $3.39M | Buy |
7,944
+7,352
| +1,242% | +$1.98M | ﹤0.01% | 3049 |
|
|
2017
Q2 | $95K | Sell |
592
-220
| -27% | -$30K | ﹤0.01% | 8707 |
|
|
2017
Q1 | $102K | Sell |
812
-276
| -25% | -$35.6K | ﹤0.01% | 8381 |
|
|
2016
Q4 | $132K | Buy |
+1,088
| New | +$170K | ﹤0.01% | 8937 |
|
Other funds holding ABEO
ACM
AIC
Jeff Yass's ABEO Position: Q2 2026 in Review
Jeff Yass reduced its Abeona Therapeutics (ABEO) stake by 55% in Q2 2026, selling an estimated $1.31M and leaving 194,377 shares worth $1.2M. The position accounts for ﹤0.01% of the portfolio, ranked #7731.
Jeff Yass first reported a position in ABEO in Q3 2016 and has held it in 28 quarters since. The position peaked at $3.7M in Q4 2025. 126 funds tracked by Wall St. Rank hold ABEO as of Q2 2026.
- Jeff Yass held 194,377 shares of Abeona Therapeutics worth $1.2M as of Q2 2026.
- Jeff Yass sold 237,993 Abeona Therapeutics shares in Q2 2026, an estimated $1.31M.
- Abeona Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #7731 holding.
- Jeff Yass first reported a position in Abeona Therapeutics in Q3 2016 and has held it in 28 quarters since.
- Jeff Yass's Abeona Therapeutics position peaked at $3.7M in Q4 2025.
- 126 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q2 2026.
Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.